RGEN (Repligen) Short Interest


RGEN Repligen Corp RGEN
83 GF Score
Price $138.47
GF Value $175.89
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Repligen Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

RGEN vs ATR, AVTR, TFX: Short Interest Comparison

For the Medical Instruments & Supplies subindustry, Repligen's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Repligen Short Interest vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Short Interest distribution charts can be found below:

* The bar in red indicates where Repligen's Short Interest falls into.


RGEN
83GF Score
Repligen Corp RGEN
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Repligen (RGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Repligen stock appears to be undervalued. The current stock price of $138.47 is trading 21.3% below its estimated GF Value™ of $175.89. GuruFocus considers Repligen to be Modestly Undervalued.

Key valuation signals for RGEN:

  • Short Interest:
  • GF Value™: $175.89 vs. price of $138.47 (21.3% below fair value)
  • GF Score™: 83/100 with 5 warning signs

No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Repligen Business Description

Other Exchanges RGN:Germany
Address 41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
83GF Score

Get the complete analysis for RGEN

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$138.47
Price
$175.89
GF Value